argenx stock: VYVGART sales rise 54% in third quarter

Published on 10/30/2026 at 14:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx stock is in focus after strong VYVGART demand in the third quarter. Regulatory and clinical milestones set the next catalysts.

Growth and pipeline milestones

VYVGART product sales reached 1.721 billion US dollars in the third quarter, up 54 percent year over year.
argenx expects a pediatric regulatory decision in February 2027 and plans an immune-mediated necrotizing myopathy filing by year-end.
Topline EMPASSION results in multifocal motor neuropathy are expected in December 2026.

Argenx, NL0010832176, Illustration mit AI erstellt.

argenx reported strong third-quarter growth on October 22, while its pipeline advanced toward several regulatory and clinical milestones. The latest company update, published by GlobeNewswire via Morningstar, said VYVGART remained the main commercial driver.

Product net sales reached 1.721 billion US dollars in the three months ended September 30, up 54 percent from 1.127 billion US dollars a year earlier and 13 percent from the second quarter. Profit for the period rose to 506 million US dollars from 344 million US dollars, while operating profit increased to 486 million US dollars from 346 million US dollars. Selling, general and administrative expenses included approximately 150 million US dollars in acquisition-related costs tied to Forte Biosciences.

Growth supports broader expansion

argenx submitted a supplemental biologics license application for VYVGART in ocular myasthenia gravis. The application for pediatric generalized myasthenia gravis was accepted for priority review, with a target FDA action date in February 2027. The company expects a VYVGART Hytrulo autoinjector to launch in the second half of 2027 for approved indications.

Positive Phase 3 ALKIVIA results support a planned filing for VYVGART Hytrulo in immune-mediated necrotizing myopathy by the end of 2026. argenx also plans an additional registrational study in dermatomyositis. Topline results from the Phase 3 EMPASSION study of empasiprubart in multifocal motor neuropathy are expected in December 2026.

Stock context for investors

argenx stock traded at 816.80 euros on Lang & Schwarz at 14:33 CEST on Friday, October 30, 2026. That was 1.64 percent above the 803.60 euros quoted in the previous report published earlier the same day. Investors can follow the real-time quote of argenx stock.